Childhood Brain Tumours may be Treated by Modified Measles Virus

by Kathy Jones on  May 28, 2010 at 6:06 PM Child Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

A modified measles virus has shown potential for treating childhood brain tumour known as medulloblastoma in a new study.

Medulloblastoma is the most common malignant central nervous system tumour of childhood, accounting for about 20 percent of paediatric brain tumours.
 Childhood Brain Tumours may be Treated by Modified Measles Virus
Childhood Brain Tumours may be Treated by Modified Measles Virus

These tumours are located in the cerebellum, the area of the brain that controls balance and other complex motor functions. Refinements in treatment have increased the 5-year survival to close to 70 percent, but treatment still involves invasive surgery, radiation therapy and chemotherapy.

"There is still an urgent need to investigate alternative therapeutic approaches that are more effective and have less toxic side effects," said study lead author Corey Raffel, chief of Neurosurgery at Nationwide Children's Hospital and a faculty member of The Ohio State University College of Medicine.

Vaccine strains of measles virus have been used to kill tumour cells in a number of tumour types including one type of adult brain tumour. One vaccine strain of measles, the Edmonston strain, targets the cell surface receptor CD46 to gain entry into susceptible cells.

"This preference most likely explains the efficacy of Edmonston strains in killing tumour cells, given the high level of expression of CD46 in multiple tumour types. It is also the reason we chose to explore a modified Edmonston's strain of measles virus for use in medulloblastoma," said Dr. Raffel.

The team's laboratory studies revealed that established medulloblastoma cell lines express the measles receptor, CD46 and that medulloblastoma specimens removed from patients have a high level of CD46 expression.

"Other oncolytic viruses have been explored as possible treatment modalities for medulloblastoma. The fact that all of the surgical medulloblastoma specimens that we examined expressed the measles virus receptor leads us to believe that measles virus may have some advantages over other viruses," said Dr. Raffel.

Having demonstrated receptor expression, the team treated the medulloblastoma cell lines with the modified measles virus. Within 72 hours, all cell lines exhibited significant tumour cell death.

The team also administered the modified measles virus to mouse models of medulloblastoma, administering treatment every other day for 10 days.

By the end of the study period, pathological review of the animals confirmed that two of the animals were free of tumour and the third had a very small amount of residual tumour. In eight of the eleven mice the primary tumour was eradicated.

"Our study demonstrates that a modified measles virus has therapeutic potential in the treatment of intracerebral medulloblastoma. These results provide initial data to be pursued with additional studies toward the goal of using the virus in a clinical trial for the treatment of medulloblastoma. Measles virus therapy could be applied to the tumour bed following surgical resection to target microscopic residual disease. This approach could potentially alleviate the need for radiation and chemotherapy," said Dr. Raffel.

The new study appears in Neuro-Oncology.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Parkinsons Disease Measles Shigellosis Parkinsons Disease Surgical Treatment Brain Brain Facts Ataxia Rashes Symptom Evaluation Language Areas in The Brain Ways to Improve your Intelligence Quotient (IQ) 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive